

14 November 2022

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex, Bandra (East)
Mumbai - 400051

Symbol: BANKA**Sub: Outcome of Board Meeting held on 14 November 2022****Ref: Regulation 30 & 33 read with sub-para 4 & 7 of Para "A" of Part "A" of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

With reference to the above-cited subject, we would like to inform you that the meeting of the Board of Directors of the Company held today i.e., Monday, 14 November 2022, the Board, inter alia, discussed, considered, and approved the following:

- a) Un-audited financial results (both standalone and consolidated) for the quarter and half ended 30 September 2022, as recommended by the Audit Committee and reviewed by Statutory Auditors.
- b) Statement of Assets and Liabilities, and Cash Flow Statement (both standalone and Consolidated) for the quarter and half ended 30 September 2022, as recommended by the Audit Committee and reviewed by Statutory Auditors.
- c) Resignation of Mr. Sri Bala Aditya Yanamandra as the Company Secretary & Compliance Officer with effect from 14 November 2022.
- d) Appointment of Ms. Archana Arigela as the Company Secretary & Compliance Officer of the Company with effect from 15 November 2022.

In this regard, we are enclosing herewith a copy of un-audited (both Standalone and Consolidated) financial results, statement of assets and liabilities, cash flow statement for the quarter and half year ended 30 September 2022, along with the Limited Review Reports received from the statutory Auditors of the Company on the said results.

The aforesaid financial results and Statements are duly approved and recommended by the Audit Committee in their meeting held on 14 November 2022.

These are also being made available on the website of the Company at www.bankabio.com

Further, For the item no.s (b) and (c), information pertaining to SESI Circular No. CIR/CFD/CMD/4/2015 dated 9 September, 2015 will be submitted separately within the prescribed timelines.

The meeting commenced at 1:00 PM and concluded at 5: 00 PM.

This is for your information and records.

Thank you

For Banka BioLoo Limited

VISHAL
MURARKA

Digitally signed
by VISHAL
MURARKA
Date: 2022.11.14
17:05:11 +05'30'

Vishal Murarka
Chief Executive Officer
(DIN 06729485)

Encls as above





Independent Auditor's Review Report on the Quarterly Unaudited Standalone and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of BANKA BIOLOO LIMITED

1. We have reviewed the accompanying Statement of unaudited standalone financial results of **BANKA BIOLOO LIMITED** for the quarter and half year ended September 30, 2022 and the Standalone Unaudited Balance Sheet and Cash Flow Statement as at September 30, 2022 (the "statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
2. This Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements.

For PRSV & Co.LLP

Chartered Accountants

Firm Registration No: S200016

Y.Venkateswarlu

Partner

Membership No: 222068



Place: Hyderabad

Date: 14-11-2022

UDIN: 22222068BDBADD2674

BANKA BIOLOO LIMITED

Statement of STANDALONE Assets and Liabilities as at 30 September 2022

Particulars	Rs. in Lacs	
	Unaudited As at 30 September, 2022	Audited As at 31 March, 2022
ASSETS		
Non-current assets		
Property, Plant and Equipment	726.83	404.75
Capital work in progress	158.23	241.78
Right-of-use assets	174.57	202.24
Intangible assets	10.52	10.19
Financial assets		
Investments	436.76	435.76
Other financial assets	163.13	216.90
Deferred tax assets (net)	27.48	7.97
Other Non current assets	63.89	-
Total non-current assets	1,761.40	1,519.60
Current assets		
Inventories	1,087.44	1,062.71
Financial assets		
Trade receivables	735.10	1,737.87
Cash and cash equivalents	150.29	29.55
Other bank balances	437.11	389.53
Loans	173.58	54.09
Other financial assets	233.62	216.20
Income tax assets	196.56	161.01
Other current assets	1,105.85	789.42
Total current assets	4,119.56	4,440.38
Total assets	5,880.96	5,959.97
EQUITY AND LIABILITIES		
Equity		
Equity share capital	1,084.66	1,084.66
Other equity	2,795.04	2,660.84
Total equity	3,879.70	3,745.50
Liabilities		
Non-current liabilities		
Financial Liabilities		
Borrowings	527.84	614.83
Lease liabilities	141.80	168.11
Provisions	43.12	29.12
Deferred tax liabilities (Net)	-	-
Total Non-current liabilities	712.75	812.06
Current liabilities		
Financial Liabilities		
Short-term borrowings	746.91	779.47
Trade payables		
Total outstanding dues of micro and small enterprise	-	7.70
Total outstanding dues of creditors other than micro and small enterprise	174.10	247.80
Short-term lease liabilities	50.68	46.33
Other financial liabilities	11.62	18.65
Other current liabilities	305.20	302.47
Total Current liabilities	1,288.51	1,402.42
Total Equity & Liabilities	5,880.96	5,959.97

For PRSV & Co. LLP
Chartered Accountants
FRN No. S200016


Y. Venkateswarlu
Partner
M.No.222068

Place: Hyderabad
Date: 14.11.2022



FOR & ON BEHALF OF BOARD OF DIRECTORS

Vishal Murarka
CEO & Executive Director
DIN: 06729485



BANKA BIOLOO LIMITED

Unaudited STANDALONE Statement of Financial Results for the quarter & half year ended 30 September 2022

Rs. in Lacs

S. No	Particulars	Quarter ended			Half Year Ended		Year ended
		Unaudited			Unaudited		Audited
		30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
1	Income						
	Revenue from Operations	1025.95	939.35	1031.29	1965.30	1834.29	3863.38
	Other income	16.93	8.11	9.26	25.04	21.31	45.37
	Total Income	1042.88	947.46	1040.55	1990.35	1855.60	3908.75
2	Expenses						
	Cost of materials consumed	98.72	174.80	298.08	273.52	445.60	774.66
	Changes in inventories of finished goods & work-in-progress	32.61	(58.33)	(61.48)	(25.72)	(68.56)	(107.80)
	Employee benefits expense	584.18	541.07	445.98	1125.25	795.19	1774.16
	Finance costs	37.45	41.33	42.59	78.78	83.73	173.13
	Depreciation and amortisation expense	28.43	31.12	20.68	59.55	40.48	94.06
	Other expenses	171.85	176.89	211.08	348.74	418.94	874.54
	Total expenses	953.24	906.87	956.92	1860.11	1715.38	3582.75
3	Profit/(loss) before tax	89.64	40.60	83.63	130.24	140.21	326.00
4	Tax expense						
	(1) Current tax	12.00	3.55	0.00	15.55	0.00	27.88
	(2) Taxes for earlier years	0.00	0.00	0.00	0.00	0.00	0.00
	(3) MAT Credit	0.00	0.00	0.00	0.00	0.00	0.00
	(4) Deferred tax	(9.32)	(10.20)	(5.66)	(19.51)	(14.27)	(7.75)
	Total Tax expense	2.68	(6.64)	(5.66)	(3.96)	(14.27)	20.13
5	Profit after tax	86.96	47.24	89.29	134.20	154.49	305.87
	Other comprehensive income						
	<i>Items that will not be reclassified to profit and loss</i>						
	Remeasurement of post-employment benefit obligations	0.00	0.00	0.00	0.00	0.00	4.51
	Income tax effect on items that will not be reclassified to	0.00	0.00	0.00	0.00	0.00	(1.10)
	Other comprehensive income for the year	0.00	0.00	0.00	0.00	0.00	3.40
	Total comprehensive income for the year	86.96	47.24	89.29	134.20	154.49	309.27
6	Paid up equity share capital (Face value Rs. 10/- each)	1084.66	1084.66	1028.11	1084.66	1028.11	1084.66
7	Earnings per share						
	Basic and Diluted Earnings per share (in Rs.)	0.80	0.44	0.87	1.24	1.50	2.97
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

For PRSV & Co. LLP
Chartered Accountants
FRN No. S200016

Y. Venkateswarlu
Partner
M.No.222068



FOR & ON BEHALF OF BOARD OF DIRECTORS

Vishal Murarka
CEO & Executive Director
DIN: 06729485



Place: Hyderabad
Date: 14.11.2022

BANKA BIOLOO LIMITED

Standalone statement of Cash flows for the year ending 30.09.2022

Rs. in lacs

Particulars	Half year ended 30 September 2022	Year ended 31 March 2022
A. Cash flows from/(used in) operating activities		
Net profit before tax	130.24	326.00
Adjustments for:	-	-
Depreciation and amortisation expense	59.55	94.06
Finance cost	67.33	155.63
Interest on Lease Rentals	11.45	17.50
Loss on sale of asset	-	0.25
Impairment of assets	-	-
Other Comprehensive	-	-
Interest income	(25.04)	(45.37)
Operating profit before working capital changes	243.52	548.07
<i>Changes in operating assets and liabilities</i>		
(Increase)/decrease in inventories	(24.74)	(259.68)
(Increase) in trade receivables	1,002.77	(570.06)
(Increase)/decrease in other financial assets	36.35	295.40
(Increase)/decrease in other current assets	(316.43)	(233.89)
(Increase)/decrease in other non-current assets	(183.38)	47.71
(Increase)/decrease in other assets	0.28	(2.20)
Increase/(Decrease) in trade payables	(81.40)	6.78
Increase/(Decrease) in other financial liabilities	(7.03)	8.48
Increase/(Decrease) in other current liabilities	2.73	129.71
Increase/(Decrease) provisions	14.00	0.86
Cash (used in)/ from operating activities	686.67	(28.82)
Tax paid	51.38	66.68
Net cash (used in)/ from operating activities	635.29	(95.50)
B. Cash flow from/(used in) investing activity		
Purchase of fixed assets	(270.72)	(316.04)
Sale of Asset	-	0.70
(Increase)/decrease in investments	(1.00)	1.00
Interest received	25.04	45.37
Net cash (used in)/from investing activities	(246.68)	(268.97)
C. Cash flows from/(used in) financing activities		
Repayment /proceeds of long term borrowings	(86.99)	28.02
Increase/(decrease) in short term borrowing	(32.56)	308.09
Payment of principle portion of lease liabilities	(33.41)	(44.05)
Interest paid	(67.33)	(155.63)
Dividend paid	-	-
Net cash (used in)/from financing activities	(220.29)	136.42
Net increase /(decrease) in cash and cash equivalents	168.33	(228.05)
Add: Cash and cash equivalents at the beginning of the year	419.08	647.13
Less: Bank deposits with less than 12 months maturity	437.11	389.53
Cash and cash equivalents at the end of the year	150.29	29.55

For PRSV & Co.LLP
Chartered Accountants
FRN No: S-200016


Y.Venkateswarlu
Partner
M.No. 222068

Place: Hyderabad
Date: 14.11.2022



FOR & ON BEHALF OF BOARD OF DIRECTORS

Vishal Murarka
CEO & Executive Director
DIN: 06729485



Notes:

1. The above unaudited Standalone Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 14 November 2022.
2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards ("INDAS") prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI .
3. The above Standalone Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
4. The Standalone Financial Results for the quarter and half year ended 30 September 2022 have been prepared following the same accounting policies as these followed for the annual financial statements for the year ended 31st March 2022.
5. Based on the internal reporting provided to the Chief Operating Decision Maker, the standalone financial results relate to manufacturing, supplying and installation of Bio toilets and related AMOC services as the only reportable primary segment of the Company as per the Ind AS 108 "Operating Segments".
6. During the financial year ended 31st March 2018, the company has completed its initial public Offer (IPO) of 10,98,000 Equity Shares of Rs.10/- each at a price of Rs.115 per share (including a premium of Rs.105 per share).
7. Proceeds from Initial Public Offer of Equity Shares have been utilized as under:

S. No	Particulars	Projected Utilization of Funds as per Prospectus	Actual Utilization of Funds till 30.09.2022	Deviation/ Variation (if any)
1	Long Term Working Capital Requirement	797.88	797.88	
2	General Corporate Purpose	231.62	231.62	
3	Issue Related Expenses-Company portion	61.10	61.08	
4	Capital expenditure at existing inoculum at Aler	75.21	75.21	
5	Capital expenditure at proposed new unit at Ibrahimpatnam	96.89	26.14	
	Total	1,262.70	1191.92	-

8. The Company has considered internal and external information up to the date of approval of these standalone financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
9. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For **Banka BioLoo Limited**



Vishal Murarka
Vishal Murarka
CEO & Executive Director
DIN: 06729485

Place: Hyderabad
Date: 14 November 2022



Independent Auditor's Review Report on the Quarterly Unaudited Consolidated and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of BANKA BIOLOO LIMITED

1. We have reviewed the accompanying Statement of Consolidated unaudited financial results of **BANKA BIOLOO LIMITED** ("the Parent") its Subsidiaries (the Parent and Subsidiaries together referred to as "the Group") and its associate for the quarter and half year ended September 30, 2022 and the Consolidated Unaudited Balance Sheet and Cash Flow Statement as at September 30, 2022 (the "statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
2. This Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Parent's Management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities.

Holding Company

BANKA BIOLOO LIMITED

Wholly owned subsidiary

1. ENZOTECH SOLUTIONS PRIVATE LIMITED
2. MEGALITER VARUNAA PRIVATE LIMITED



Associate

1. SAI BANKA SPV PRIVATE LIMITED
2. SUSTAINABLE SANITATION INDUSTRY ASSOCIATION

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 and 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements.
6. We did not review the interim financial results of 1 wholly owned subsidiary included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs. 160.47 Lakhs and Rs. 385.59 Lakhs, total net profit after tax of Rs. 0.24 Lakhs and Rs. 6.44 Lakhs and total comprehensive income of Rs. 0.24 Lakhs and Rs. 6.44 Lakhs for the quarter ended September 30, 2022, and for the period from April 30, 2022, to September 30, 2022, respectively, and cash flows (net) of Rs.174.61 Lakhs for the period from April 30, 2022, to September 30, 2022, as considered in the consolidated unaudited financial results. These interim financial statements / financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the wholly owned subsidiary is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.
7. The consolidated unaudited financial results also include the Group's share of net profit/(loss) after tax of Rs. 0.71 Lakhs and Rs. 3.17 Lakhs and total comprehensive income / (loss) of Rs. 0.71 Lakhs and Rs. 3.17 Lakhs for the quarter ended September 30, 2022, and for the period from April 30, 2022, to September 30, 2022, respectively, as considered in the consolidated unaudited financial results, in respect of 2 associates, based on their interim financial statements/ financial information/ financial results which have not been reviewed/audited by their auditors. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group

For PRSV & Co. LLP

Chartered Accountants

Firm Registration No: S200016

Y.Venkateswarlu

Partner

Membership No: 222068

Place: Hyderabad

Date: 14-11-2022



UDIN: 22222068BDBAPW9528

BANKA BIOLOO LIMITED
Unaudited Consolidated Assets and Liabilities as at 30 September 2022

(In Lakhs)

Particulars	Unaudited	Audited
	As at 30 September, 2022	As at 31 March, 2022
ASSETS		
Non-current assets		
Property, plant and equipment	752.52	432.67
Capital work in progress	158.23	241.78
Right-to-use asset	174.57	202.24
Intangible assets	10.52	10.19
Goodwill on consolidation	31.51	31.51
Financial assets	-	-
Investments	8.18	5.01
Other financial assets	163.76	217.53
Deffered tax assets (net)	26.46	6.94
Other non-current assets	63.89	-
Total non-current assets	1,389.64	1,147.88
Current assets		
Inventories	1,361.57	1,340.56
Financial assets	-	-
Trade receivables	1,077.18	2,035.93
Cash and cash equivalents	150.46	31.92
Other bank balances	452.18	396.11
Loans	20.96	27.57
Other financial assets	374.75	259.13
Income tax assets	196.56	190.67
Other current assets	1,283.02	975.66
Total current assets	4,916.68	5,257.55
Total assets	6,306.32	6,405.43
EQUITY AND LIABILITIES		
Equity		
Equity share capital	1,084.66	1,084.66
Other equity	2,809.35	2,665.53
Equity attributable to shareholders of the company	3,894.00	3,750.19
Non-controlling interests		
Total equity	3,894.00	3,750.19
Liabilities		
Non-current liabilities		
Financial Liabilities	-	-
Borrowings	593.84	742.91
Lease liabilities	141.80	168.11
Provisions	43.12	29.12
Deferred tax liabilities (Net)	-	-
Total Non-current liabilities	778.76	940.14
Current liabilities		
Financial Liabilities	-	-
Short-term borrowings	848.86	892.25
Trade payables	-	-
Total outstanding dues of micro and small enterprises	63.13	70.64
Total outstanding dues of creditors other than micro and small enterprises	232.72	295.29
Lease liabilities	50.68	46.33
Other financial liabilities	132.96	18.65
Other current liabilities	305.20	391.94
Total Current liabilities	1,633.56	1,715.11
Total Equity & Liabilities	6,306.32	6,405.43


For PRSV & Co. LLP
Chartered Accountants
FRN No. S-200016

Y. Venkateswarlu
Partner
M.No.222068

Place: Hyderabad
Date: 14.11.2022

FOR & ON BEHALF OF BOARD OF DIRECTORS

Vishal Murarka
CEO & Executive Director
DIN: 06729485



BANKA BIOLOO LIMITED


Unaudited Consolidated Statement of Financial Results for the quarter ended 30 Sept 2022

(In Lakhs)


S. No	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2022 Unaudited	30.06.2022 Audited	30.09.2021 Unaudited	30.09.2022 Unaudited	30.09.2021 Unaudited	31.03.2022 Audited
1	Income						
	Revenue from Operations	1,235.79	1,110.23	1,031.29	2,346.02	1,834.29	3,875.08
	Other operating revenue	-	-	-	-	-	-
	Other income	14.35	10.37	9.26	24.72	21.31	45.37
	Total Income	1,250.14	1,120.61	1,040.55	2,370.74	1,855.60	3,920.45
2	Expenses						
	Cost of materials consumed	236.44	273.37	298.08	509.81	445.60	778.67
	Changes in inventories of finished goods & work-in-progress	30.14	(68.57)	(61.48)	(38.43)	(68.56)	(106.54)
	Employee benefits expense	618.14	575.77	445.98	1,193.92	795.19	1,776.42
	Finance costs	43.72	46.47	46.75	90.19	87.89	173.78
	Depreciation and amortisation expense	29.58	32.33	20.68	61.91	40.48	94.15
	Other expenses	200.07	214.44	206.92	414.51	414.77	875.79
	Total expenses	1,158.10	1,073.81	956.92	2,231.91	1,715.38	3,592.27
3	Share of profit/(loss) of Associates	0.71	2.46	(0.93)	3.17	(1.55)	2.71
4	Profit/(loss) before tax	92.75	49.26	82.69	142.00	138.66	330.89
5	Tax expense						
	(1) Current tax	14.16	3.55	-	17.72	-	27.88
	(2) Taxes for earlier years	-	-	-	-	-	-
	(3) MAT Credit	-	-	-	-	-	-
	(4) Deferred tax	(9.32)	(10.20)	(5.66)	(19.52)	(14.27)	(7.75)
	Total Tax expense	4.84	(6.65)	(5.66)	(1.81)	(14.27)	20.13
6	Profit after tax	87.91	55.91	88.35	143.81	152.94	310.76
	Other comprehensive income						
	<i>Items that will not be reclassified to profit and loss</i>						
	Remeasurement of post-employment benefit obligations	-	-	-	-	-	4.51
	Income tax effect on items that will not be reclassified	-	-	-	-	-	(1.10)
	Other comprehensive income for the year	-	-	-	-	-	3.40
	Total comprehensive income for the year	87.91	55.91	88.35	143.81	152.94	314.17
	Attributable to						
	Shareholders of the Company	87.91	55.91	88.35	143.81	152.94	314.17
	Non controlling interest	-	-	-	-	-	-
7	Paid up equity share capital (Face value Rs. 10/- each)	1,084.66	1,084.66	1,028.11	1,084.66	1,028.11	1,084.66
8	Earnings per share						
	Basic and Diluted Earnings per share (in Rs.)	0.81	0.52	0.87	1.33	1.50	3.02
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

FOR & ON BEHALF OF BOARD OF DIRECTORS

For PRSV & Co. LLP
Chartered Accountants
FRN No. S-200016


Y. Venkateswarlu
Partner
M.No.222068


Vishal Murarka
CEO & Executive Director
DIN: 06729485



Place: Hyderabad
Date: 14.11.2022


BANKA BIOLOO LIMITED

Unaudited Consolidated statement of Cash flows for the period ending 30 Sept 2022


(In Lakhs)

Particulars	Period ended 30.09.2022	Year ended 31 March 2022
A. Cash flows from/(used in) operating activities		
Net profit before tax	142.00	330.89
Adjustments for:	-	-
Depreciation and amortisation expense	61.91	94.15
Finance cost	78.74	156.29
Interest on Lease Rentals	11.45	17.50
Loss on sale of asset	-	0.25
Impairment of assets	-	-
Other Comprehensive	-	-
Interest income	(24.72)	(45.37)
Operating profit before working capital changes	269.38	553.70
<i>Changes in operating assets and liabilities</i>	-	-
(Increase)/decrease in inventories	(21.00)	(259.68)
(Increase)/decrease in trade receivables	958.75	(570.06)
(Increase)/decrease in other financial assets	(61.85)	295.40
(Increase)/decrease in other current assets	(307.36)	(233.89)
(Increase)/decrease in other non-current assets	(57.28)	47.71
(Increase)/decrease in other assets	27.77	(2.20)
Increase/(Decrease) in trade payables	(70.08)	6.78
Increase/(Decrease) in other financial liabilities	114.31	49.41
Increase/(Decrease) in other current liabilities	(86.74)	134.69
Increase/(Decrease) provisions	14.00	0.86
Cash (used in)/from operating activities	779.90	22.72
Tax paid	51.38	66.68
Net cash (used in)/ from operating activities	728.52	(43.96)
B. Cash flow from/(used in) investing activity	-	-
Purchase of fixed assets	(270.86)	(316.04)
Sale of Asset	-	0.70
(Increase)/decrease in investments	(3.17)	(1.68)
Interest received	24.72	45.37
Net cash (used in)/from investing activities	(249.30)	(271.65)
C. Cash flows from/(used in) financing activities	-	-
Repayment /proceeds of long term borrowings	(149.07)	28.02
Increase/(decrease) in short term borrowing	(43.39)	267.16
Payment of lease liabilities	(33.41)	(44.05)
Interest paid	(78.74)	(155.63)
Dividend paid	-	-
Net cash (used in)/from financing activities	(304.60)	95.50
Net increase /(decrease) in cash and cash equivalents	174.61	(220.12)
Add: Cash and cash equivalents at the beginning of the year	428.03	648.14
Less: Bank deposits with less than 12 months maturity	452.18	396.11
Cash and cash equivalents at the end of the year	150.46	31.92

 For PRSV & Co.LLP
 Chartered Accountants
 FRN No: S200016

 Y. Venkateswarlu
 Partner
 M.No.222068


FOR & ON BEHALF OF BOARD OF DIRECTORS


 Vishal Murarka
 CEO & Executive Director
 DIN: 06729485

 Place: Hyderabad
 Date: 14.11.2022

Notes:

1. The above statement of unaudited Consolidated Financial Results was reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 14 November 2022.
2. The Consolidated Financial Results have been prepared in accordance with Indian Accounting Standards (“INDAS”) prescribed under section 133 of the Companies Act 2013 (“the Act”) read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI .
3. The consolidated financial results of the Group include the results of the Company and results of the following entities.

Name of the entity	Status
Enzotech Solutions Pvt Ltd	Wholly owned subsidiary
Megaliter Varunaa Pvt Ltd	Wholly owned subsidiary
Sai Banka SPV Pvt Ltd	Associate
Sustainable Sanitation Industry Association	Associate

4. The above Consolidated Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
5. The Company has considered internal and external information up to the date of approval of these Consolidated financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
6. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.



Place: Hyderabad
Date: 14 November 2022

For **Banka BioLoo Limited**



Vishal Murarka
CEO & Executive Director
DIN: 06729485

14 November 2022

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex
Bandra (East)
Mumbai - 400051

Symbol: BANKA

Sub: Statement of Deviation(s) or Variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter ended 30 September 2022

Dear Sir/Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/ CFD/CMDI/162/2019 dated December 24, 2019, we hereby confirm that during the quarter ended 30 September 2022, there was no deviation or variation in the utilisation of proceeds of the IPO from the objects stated in the Prospectus dated April 07, 2022.

A statement of deviation or variation for the quarter ended 30 September 2022, duly reviewed by the Audit Committee of the Company at its meeting held on 14 November 2022, enclosed herewith for your records.

You are requested to take the same on your record.

Thank you.

For Banka BioLoo Limited

VENKATA
RAMA KRISHNA
TADEPALLI

Digitally signed by
VENKATA RAMA
KRISHNA TADEPALLI
Date: 2022.11.14
17:04:12 +05'30'

Tadepalli Venkata Rama Krishna
CFO & Executive Director
DIN: 07977695

Statement of Deviation/Variation in utilisation of funds raised

Name of listed entity	Banka bioloo limited					
Mode of Fund Raising	Public Issue					
Date of Raising Funds	5 February 2022 to 16 February 2022					
Amount Raised (INR in Lakhs)	1,262.70					
Report filed for Quarter ended	30 September 2022					
Monitoring Agency	Applicable/ Not Applicable					
Monitoring Agency Name, if applicable	Not Applicable					
Is there a Deviation/ Variation in use of funds raised	Yes/No					
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable					
If Yes, Date of shareholder Approval	Not Applicable					
Explanation for the Deviation/ Variation	Not Applicable					
Comments of the Audit Committee after review	Not Applicable					
Comments of the auditors, if any	Not Applicable					
Objects for which funds have been raised and where there has been a deviation, in the following table (INR in Lakhs)						
Original Objects	Modified Objects, if any	Original Allocation	Modified Allocation, if any	Funds Utilised	Amount of Deviation /variation for the quarter according to applicable object	Remarks if any
Long-Term Working Capital Requirement	NA	797.88	NA	797.88	NA	No Deviation
General Corporate Purpose	NA	231.62	NA	231.62	NA	No Deviation
Issue Related Expenses-Company portion	NA	61.10	NA	61.08	NA	No Deviation
Capital expenditure at existing inoculum generation plant at Aler	NA	75.21	NA	75.21	NA	No Deviation
Capital expenditure at proposed new unit at Ibrahimpatnam	NA	96.89	NA	26.42	NA	No Deviation
Deviation or variation could mean:						
(a) Deviation in the objects or purposes for which the funds have been raised or						
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or						
(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc						

For Banka BioLoo Limited

VENKATA
RAMA KRISHNA
TADEPALLI

Digitally signed by
VENKATA RAMA
KRISHNA TADEPALLI
Date: 2022.11.14
17:03:34 +05'30'

Tadepalli Venkata Rama Krishna
CFO & Executive Director
DIN: 07977695

Date: 14 November 2022

Place: Hyderabad